• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

    2/13/23 4:05:40 PM ET
    $CMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMRX alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    CHIMERIX, INC.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    16934W106

     

    (CUSIP Number)

     

    James Silverman, One Boston Place, 26th Floor, Boston, MA 02108, 617-229-5085

     

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    12/30/2022

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 16934W106 13G Page 2 of 6 Page

     

    1. NAMES OF REPORTING PERSONS
      Opaleye Management Inc.
       
     

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    20-5648796

       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
       
      (a) [  ]
      (b) [  ]
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Massachusetts

    NUMBER OF SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON WITH

    5. SOLE VOTING POWER
       
      0
    6. SHARED VOTING POWER
       
      0
    7. SOLE DISPOSITIVE POWER
       
      0
    8. SHARED DISPOSITIVE POWER
       
      0

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
       
      [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      0.0%
    12. TYPE OF REPORTING PERSON (see instructions)
       
      CO

     

     
     

     

    CUSIP No. 16934W106 13G Page 3 of 6 Page

     

    Item 1.

     

      (a) Name of Issuer: Chimerix, Inc. (the “Company”).
         
      (b) Address of Issuer’s Principal Executive Offices: 2505 Meridian Parkway, Suite 100, Durham, NC 27713

     

    Item 2.

     

      (a) Name of Person Filing: This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons” with respect to the shares of common stock of the Company:
         
        Opaleye Fund
         
        Opaleye, L.P. (the “Opaleye Fund”), a private fund formed in the state of Delaware.
         
        Investment Manager
         
       

    Opaleye Management Inc. (the “Investment Manager”), with respect to the shares of common stock held by the Opaleye Fund, a private fund to which the Investment Manager serves as investment manager. The Investment Manager also serves as a portfolio manager for a separate managed account (the “Managed Account”) and may be deemed to indirectly beneficially own securities owned by the Managed Account. The Investment Manager disclaims beneficial ownership of the shares held by the Managed Account.

       
        Reporting Individual
         
        Mr. James Silverman (the “Reporting Individual”), with respect to the shares of common stock held by the Opaleye Fund. Mr. Silverman is the President of the Investment Manager.
         
      (b)

    Address of the Principal Office or, if none, residence

     

    One Boston Place, 26th Floor, Boston, MA 02108

         
      (c) Citizenship
         
        Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person.
         
      (d) Title of Class of Securities
         
        Common Stock, $0.001 par value per share
         
      (e) CUSIP Number 16934W106

     

     
     

     

    CUSIP No. 16934W106 13G Page 4 of 6 Page

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned: 0
           
      (b) Percent of class: 0.0%
           
      (c) Number of shares as to which the person has: 0
           
        (i) Sole power to vote or to direct the vote .0
           
        (ii) Shared power to vote or to direct the vote 0
           
        (iii) Sole power to dispose or to direct the disposition of 0
           
        (iv) Shared power to dispose or to direct the disposition of 0

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Not applicable

     

     
     

     

    CUSIP No. 16934W106 13G Page 5 of 6 Page

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

    Item 10. Certification.

     

      (a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No. 16934W106

    13G Page 6 of 6 Page

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    02/13/2023

    Date

     

    /James Silverman/

    Signature

     

    James Silverman

    Managing Member of Opaleye GP LLC , the General Partner of Opaleye, L.P.
    Name/Title

     

     

     

    Get the next $CMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CMRX

    DatePrice TargetRatingAnalyst
    5/23/2023$7.00Outperform
    Robert W. Baird
    9/7/2022$7.00Overweight
    CapitalOne
    12/22/2021$21.00 → $24.00Buy
    HC Wainwright & Co.
    11/22/2021$19.00 → $21.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

      New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

      3/21/25 6:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). The stock options have an exercise price per share equal to Chimerix's closing trading price as of the grant date. The stock options have a 10-year term and will vest over four years, wi

      3/7/25 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

      -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline- -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz" or the "Company") and Chimerix (NASDAQ:CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both compani

      3/5/25 7:00:00 AM ET
      $CMRX
      $JAZZ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Vakiener Victoria

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:17:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Sherman Michael A. returned $3,620,138 worth of shares to the company (423,408 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:16:42 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO and CCO Riga Thomas J returned $520,079 worth of shares to the company (60,828 units at $8.55), closing all direct ownership in the company (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      4/21/25 4:15:59 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/14/24 5:01:40 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chimerix Inc. (Amendment)

      SC 13G/A - CHIMERIX INC (0001117480) (Subject)

      2/12/24 6:06:37 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Chimerix Inc.

      SC 13G - CHIMERIX INC (0001117480) (Subject)

      9/29/23 4:54:06 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Financials

    Live finance-specific insights

    See more
    • Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

      New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2024. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chi

      3/21/25 6:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

      Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday, December 10 at 8:30 AM ET DURHAM, N.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that, following extensive dialogue with the U.S. Food and Drug Administration (FDA), the Company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for recu

      12/9/24 4:01:00 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

      – Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review – – Alignment with TGA to Submit Dordaviprone for Provisional Approval in Australia – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the third quarter ended September 30, 2024 and provided an operational update. "We have sustaine

      11/7/24 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Chimerix with a new price target

      Robert W. Baird initiated coverage of Chimerix with a rating of Outperform and set a new price target of $7.00

      5/23/23 7:29:20 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Chimerix with a new price target

      CapitalOne initiated coverage of Chimerix with a rating of Overweight and set a new price target of $7.00

      9/7/22 8:57:44 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Chimerix with a new price target

      HC Wainwright & Co. reiterated coverage of Chimerix with a rating of Buy and set a new price target of $24.00 from $21.00 previously

      12/22/21 6:12:39 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Middleton Fred A bought $16,522 worth of shares (17,295 units at $0.96) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      11/20/23 3:28:44 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $2,489 worth of shares (2,705 units at $0.92) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      11/13/23 4:39:41 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Middleton Fred A bought $19,636 worth of shares (20,000 units at $0.98) (SEC Form 4)

      4 - CHIMERIX INC (0001117480) (Issuer)

      9/26/23 3:58:48 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Chimerix Inc.

      15-12G - CHIMERIX INC (0001117480) (Filer)

      5/1/25 8:51:45 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Chimerix Inc.

      EFFECT - CHIMERIX INC (0001117480) (Filer)

      4/23/25 12:15:12 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chimerix Inc.

      S-8 POS - CHIMERIX INC (0001117480) (Filer)

      4/21/25 4:54:30 PM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Chimerix Appoints Marc D. Kozin to Board of Directors

      DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

      3/21/24 7:00:00 AM ET
      $CMRX
      $UFPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Chimerix Appoints Lisa Decker to Board of Directors

      DURHAM, N.C., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Lisa Decker, Chief Business Officer at IGM Biosciences, has been appointed to Chimerix's Board of Directors. Ms. Decker replaces Catherine Gilliss PhD, RN, FAAN, who is simultaneously retiring from the Chimerix Board after nearly 10 years of service. "We are delighted to welcome Lisa to the Chimerix Board of Directors. She brings a wealth of scientific expertise, oncology drug development and business development experience that will be important assets to

      12/29/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer

      DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. "We are excited to welcome Tom to the Chimerix team as his leadership and extensive market knowledge will be a great asset as we advance ONC201 toward commercialization," said Mike Andriole, Chief Executive Officer of Chimerix. "Tom's in-depth oncology experience in commercial launch readiness, brand marketing, market access, and reimbursement will accelerate our readiness efforts

      11/16/23 7:00:00 AM ET
      $CMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care